Personalis, Inc. (NASDAQ:PSNL) Receives $11.50 Average Price Target from Analysts

Personalis, Inc. (NASDAQ:PSNL) has been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $11.50.

Several analysts recently issued reports on PSNL shares. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Morgan Stanley reduced their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Guggenheim increased their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research increased their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th.

Personalis Trading Up 9.2%

NASDAQ PSNL opened at $6.07 on Thursday. The firm has a market capitalization of $635.41 million, a price-to-earnings ratio of -6.67 and a beta of 1.96. The firm’s 50 day simple moving average is $6.97 and its 200 day simple moving average is $8.25. Personalis has a 1 year low of $3.84 and a 1 year high of $11.50.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.05. The business had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. On average, equities research analysts forecast that Personalis will post -1.01 earnings per share for the current year.

Hedge Funds Weigh In On Personalis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aberdeen Group plc lifted its stake in Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the last quarter. AIGH Capital Management LLC lifted its stake in Personalis by 4.5% in the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after purchasing an additional 168,143 shares during the last quarter. Oracle Investment Management Inc. bought a new position in Personalis in the 3rd quarter valued at approximately $1,496,000. ARK Investment Management LLC lifted its stake in Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after purchasing an additional 802,268 shares during the last quarter. Finally, D.A. Davidson & CO. bought a new position in Personalis in the 4th quarter valued at approximately $1,158,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.